Table 2.

Efficacy outcomes

	Mavrilimumab group (n=21)	Placebo group (n=19)	p value
Primary endpoint
Patients alive and off supplemental oxygen therapy at day 14	12 (57%)	9 (47%)	0·76*
Secondary endpoints
Patients alive and without respiratory failure at day 28	20 (95%)	15 (79%)	0·43*
Mortality at day 28	1 (5%)	3 (16%)	0·22†
Exploratory endpoints
Mortality at day 60	1 (5%)	4 (21%)	0·11†
Duration of hospitalisation, days	7·5 (6·0–11·0)	8·0 (6·0–10·0)	0·92‡

Data are n (%) or median (IQR).

^*p value from generalised Wilcoxon test.

^†p value from log-rank test.

^‡p value from Wilcoxon rank-sum test.